Gossamer Bio, Inc.
NASDAQ:GOSS
1.02 (USD) • At close January 3, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Gossamer Bio, Inc. |
Symbool | GOSS |
Munteenheid | USD |
Prijs | 1.02 |
Beurswaarde | 231,136,080 |
Dividendpercentage | 0% |
52-weken bereik | 0.499 - 1.6 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Faheem Hasnain |
Website | https://www.gossamerbio.com |
An error occurred while fetching data.
Over Gossamer Bio, Inc.
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)